Response to the Letter Regarding “Methodological Considerations in Real‐World Evaluation of Durvalumab Plus Tremelimumab for Unresectable Hepatocellular Carcinoma”
0 citations
Abstract
Data supporting the findings of this study are available from the corresponding author upon reasonable request, subject to institutional review board approval and execution of appropriate data sharing agreements.
// Source
Authors: Toshifumi Tada, Tomomitsu Matono, Takashi Kumada, the RELPEC Group
Institutions: Kobe University, Himeji Medical Center, Himeji Red Cross Hospital, Gifu Kyoritsu University